StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Cartesian Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $68.39M, up 30.9% year over year. For fiscal 2025 it was $58.03M, up 28.7% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $72.38M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$58.03M+28.7%
FY2024Dec 31, 2024$45.11M-36.7%
FY2023Dec 31, 2023$71.26M-1.5%
FY2022Dec 31, 2022$72.38M+5.3%
FY2021Dec 31, 2021$68.74M+26.1%
FY2020Dec 31, 2020$54.51M+27.5%
FY2019Dec 31, 2019$42.74M-10.4%
FY2018Dec 31, 2018$47.69M+5.6%
FY2017Dec 31, 2017$45.17M+52.1%
FY2016Dec 31, 2016$29.70M+29.3%
FY2015Dec 31, 2015$22.98M+119.1%
FY2014Dec 31, 2014$10.49M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$20.43M+37.4%
Q1 FY2026Mar 31, 2026$19.46M+32.6%
Q4 FY2025Dec 31, 2025$14.69M+29.9%
Q3 FY2025Sep 30, 2025$13.80M+21.1%
Q2 FY2025Jun 30, 2025$14.87M+17.4%
Q1 FY2025Mar 31, 2025$14.67M+50.7%
Q4 FY2024Dec 31, 2024$11.31M-48.3%
Q3 FY2024Sep 30, 2024$11.40M-12.3%
Q2 FY2024Jun 30, 2024$12.66M-28.8%
Q1 FY2024Mar 31, 2024$9.74M-47.7%
Q4 FY2023Dec 31, 2023$21.85M+15.2%
Q3 FY2023Sep 30, 2023$13.00M-21.4%
Q2 FY2023Jun 30, 2023$17.78M-7.3%
Q1 FY2023Mar 31, 2023$18.62M+5.3%
Q4 FY2022Dec 31, 2022$18.97M-6.6%
Q3 FY2022Sep 30, 2022$16.54M-21.1%
Q2 FY2022Jun 30, 2022$19.18M+32.6%
Q1 FY2022Mar 31, 2022$17.69M+36.0%
Q4 FY2021Dec 31, 2021$20.32M+34.6%
Q3 FY2021Sep 30, 2021$20.95M+50.1%
Q2 FY2021Jun 30, 2021$14.46M+34.8%
Q1 FY2021Mar 31, 2021$13.00M-11.7%
Q4 FY2020Dec 31, 2020$15.09M-0.4%
Q3 FY2020Sep 30, 2020$13.96M+72.3%
Q2 FY2020Jun 30, 2020$10.73M-11.6%
Q1 FY2020Mar 31, 2020$14.72M+100.2%
Q4 FY2019Dec 31, 2019$15.15M+47.7%
Q3 FY2019Sep 30, 2019$8.10M-31.8%
Q2 FY2019Jun 30, 2019$12.13M-15.8%
Q1 FY2019Mar 31, 2019$7.35M-34.0%
Q4 FY2018Dec 31, 2018$10.26M-24.7%
Q3 FY2018Sep 30, 2018$11.89M+25.1%
Q2 FY2018Jun 30, 2018$14.41M+31.0%
Q1 FY2018Mar 31, 2018$11.14M+0.9%
Q4 FY2017Dec 31, 2017$13.62M+23.5%
Q3 FY2017Sep 30, 2017$9.50M+57.8%
Q2 FY2017Jun 30, 2017$10.99M–
Q1 FY2017Mar 31, 2017$11.04M–
Q4 FY2016Dec 31, 2016$11.03M–
Q3 FY2016Sep 30, 2016$6.02M–

More Cartesian Therapeutics figures

See a number that looks wrong?